Caribou Biosciences, Inc. (CRBU) vs Neumora Therapeutics, Inc. (NMRA)

Caribou Biosciences, Inc. and Neumora Therapeutics, Inc. are both Biotechnology companies. Caribou Biosciences, Inc. and Neumora Therapeutics, Inc. are of similar size ($135.3M and $134.0M). Neumora Therapeutics, Inc. has the higher net margin (0.00% vs −1,030.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Caribou Biosciences, Inc. leads on 8 and Neumora Therapeutics, Inc. on 5.

Valuation

Metric CRBU NMRA Biotechnology median
P/E n/m n/m 7.88
P/S 12.58 n/m 11.47
P/B 1.29 2.83 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.39 n/m 10.73
Earnings yield (86.40%) (180.88%) (28.84%)
Free cash flow yield (105.20%) (143.21%) (23.03%)

Profitability

Metric CRBU NMRA Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (1,090.90%) 0.00% 0.00%
Net margin (1,030.42%) 0.00% 0.00%
Free cash flow margin (1,323.30%) 0.00% 0.00%
Return on equity (78.27%) (187.11%) (57.72%)
Return on assets (56.87%) (121.89%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBU NMRA Biotechnology median
Revenue growth (TTM) 10.02% — 5.64%
EPS growth (last fiscal year) 3.64% 5.23% —
Revenue growth, 5-year CAGR (2.03%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CRBU NMRA Biotechnology median
Debt to equity 0.00 1.19 0.00
Current ratio 6.49 4.50 4.73
Net debt to EBITDA 0.96 0.53 0.96

Dividend

Metric CRBU NMRA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CRBU NMRA Biotechnology median
Market cap 134.01m 135.29m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack